Newest FDA approval could boost Partner Therapeutics' Lynnwood plant
The success of Partner Therapeutics' leukemia drug could lead to an increase in hiring and expansion of its 87,000-square-foot manufacturing facility, which sits on a 16-acre parcel. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 20, 2018 Category: Pharmaceuticals Authors: Casey Coombs Source Type: news

Newest FDA approval could boost Partner Therapeutics' Lynnwood plant
The success of Partner Therapeutics' leukemia drug could lead to an increase in hiring and expansion of its 87,000-square-foot manufacturing facility, which sits on a 16-acre parcel. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 20, 2018 Category: Biotechnology Authors: Casey Coombs Source Type: news

Survival Longer With Obinutuzumab Compared to Rituximab in CLL Survival Longer With Obinutuzumab Compared to Rituximab in CLL
New longer-term results with overall survival data confirm the superiority of the newer agent over the earlier-generation anti-CD20 drug rituximab for previously untreated chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 20, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO ® (blinatumomab) Label
BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., June 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO® (blinatumomab) based on the overall survival (OS) data from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). "BLINCYTO is the first single agent immunotherapy to demonstrate superior overall survival benefit ov...
Source: Amgen News Release - June 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Novel CD22 CAR-T Works After CD19 Product Failed Novel CD22 CAR-T Works After CD19 Product Failed
A novel CAR T-cell therapy directed against CD22 worked in children with acute lymphoblastic leukemia who had previously progressed after receiving CD19-directed CAR T-cell therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

‘Supercharged’ Immunotherapy Could Target Mesothelioma Cell Protein
Standard mesothelioma treatment options include surgery, radiation therapy, chemotherapy and multimodal therapy. These standard therapies do not offer a cure for people with mesothelioma, and that’s why scientists continue searching for better ways to treat the disease. Researchers at the Scripps Research Institute in Jupiter, Florida, have created a precision medicine approach that targets a protein on the surface of cancer cells to kill tumors. Although the drug was not specifically designed for mesothelioma patients, it may offer a more effective way to manage the disease in the future. The treatment is a type of...
Source: Asbestos and Mesothelioma News - June 18, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

How LGL T-Cell Leukemia at 19 Gave Me Empathy for My Patients —and My Colleagues
Late last year, ONCOLOGY hosted a writing contest on Cancer Network, in which we asked our readers to share their personal experiences with delivering bad news. Dr. Trevor Bayliss submitted a piece about his experience as a young patient, and how that influenced his decision to become an oncologist. (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2018 Category: Cancer & Oncology Authors: Trevor J. Bayliss, MD Source Type: news

AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
83 percent (n=100) of 121 patients who achieved undetectable minimal residual disease (uMRD) at the end of combination therapy with VenR (n=194), maintained uMRD and were progression-free at 13.8 months of follow-up[1] uMRD response rates were consisten... Biopharmaceuticals, Oncology AbbVie, MURANO trial, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 15, 2018 Category: Pharmaceuticals Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the final analysis of the CLL11 study evaluating Gazyva®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: World Pharma News)
Source: World Pharma News - June 15, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Media News)
Source: Roche Media News - June 15, 2018 Category: Pharmaceuticals Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Investor Update)
Source: Roche Investor Update - June 15, 2018 Category: Pharmaceuticals Source Type: news

Without 'yoga and chardonnay' leukemia stem cells are stressed to death
(University of Colorado Anschutz Medical Campus) University of Colorado Cancer Center researchers nix leukemia stem cell (LSC) stress-relief pathway to kill LSCs without harming healthy blood stem cells, paving the way for new therapies targeting these most dangerous cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 14, 2018 Category: Cancer & Oncology Source Type: news

University of Colorado Cancer Centers Study Shows that without “Yoga...
Researchers successfully target leukemia stem cells while leaving healthy blood stem cells unharmed, paving the way for "sea change" in the way we treat acute myeloid leukemia.(PRWeb June 14, 2018)Read the full story at https://www.prweb.com/releases/2018/06/prweb15553957.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 14, 2018 Category: Pharmaceuticals Source Type: news

Basics: Secrets of the Y Chromosome
It ’ s not just what makes males into males. The sex chromosome also influences health in hidden ways, some experts believe, and may even explain why men have shorter life spans. (Source: NYT Health)
Source: NYT Health - June 11, 2018 Category: Consumer Health News Authors: NATALIE ANGIER Tags: Chromosomes Gender Genetics and Heredity Men and Boys Alzheimer's Disease Sperm Leukemia Page, David C Sayres, Melissa Wilson Research Source Type: news

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche, announced today that the United States Food and Drug Administration (FDA) has approved Venclexta ® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. (Source: Roche Media News)
Source: Roche Media News - June 11, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche, announced today that the United States Food and Drug Administration (FDA) has approved Venclexta ® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - June 11, 2018 Category: Pharmaceuticals Source Type: news

The cancer revolution: How you can benefit from a new test which could mean no more chemo
Mike Brandon, 34, from Bristol was diagnosed with chronic lymphocytic leukaemia which is deemed untreatable in the UK but he was able to undergo specialised life-saving therapy in the US. (Source: the Mail online | Health)
Source: the Mail online | Health - June 10, 2018 Category: Consumer Health News Source Type: news

Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia
South San Francisco, CA -- June 8, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Rituxan ... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 8, 2018 Category: Drugs & Pharmacology Source Type: news

More Women With Breast Cancer May Soon Be Skipping Chemo. Here ’s Why
Phyllis Lacetti found her own breast cancer when she felt an abnormal lump in her right breast in 2007. A nurse at Montefiore Medical Center, she had a lumpectomy to remove it, but an MRI afterward revealed remaining cancer cells, so she opted to get a mastectomy. Her cancer doctor recommended she get chemotherapy to ensure that her cancer wouldn’t recur, since Lacetti’s family history put her at high risk. Her sister and father had died of leukemia, and her brother passed away from thyroid cancer. Chemotherapy, he said, was her best option for preventing the cancer from returning. But Lacetti was reticent abo...
Source: TIME: Health - June 7, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer healthytime Source Type: news

A Promising Cancer Treatment Made Patients Worse, Not Better
For an unusual form of lymphoma, an immunotherapy drug made the disease more aggressive. A cautionary tale. (Source: NYT Health)
Source: NYT Health - June 5, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Immunotherapy Leukemia Viruses Cancer National Institutes of Health New England Journal of Medicine Dr. Murali Janakiram Dr. Lee Ratner Source Type: news

Ibrutinib Plus Venetoclax Shows Promising Activity Against CLL
Bryant FurlowJun 4, 2018In CAPTIVATE, first-line ibrutinib plus venetoclax yielded a high rate of undetectable residual disease, without new safety signals, in chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Roche presents new data across a range of blood cancers at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche presented new data from studies in several blood cancers, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML) at the 2018 ASCO Annual Meeting, 1-5 June, in Chicago, IL, United States. (Source: Roche Investor Update)
Source: Roche Investor Update - June 3, 2018 Category: Pharmaceuticals Source Type: news

Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions
(University of Texas M. D. Anderson Cancer Center) Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2018 Category: Cancer & Oncology Source Type: news

Structure of protein pair provides blueprint for future drugs
(Walter and Eliza Hall Institute) Walter and Eliza Hall Institute researchers have visualized for the first time how the protein SOCS1 'switches off' cell signalling to dampen immune responses and block cancer growth.The atomic-level structure of SOCS1 binding to its partner protein JAK could guide the development of drugs that alter disease-causing cell signalling pathways, and may have applications for treating some blood cancers, including leukaemias. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2018 Category: International Medicine & Public Health Source Type: news

Phase I trial finds experimental drug safe in treating chronic lymphocytic leukemia
(University of California - San Diego) Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the 'stemness' of chronic leukemia cancer (CLL) cells -- their ability to self-renew and resist terminal differentiation and senescence. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2018 Category: International Medicine & Public Health Source Type: news

Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers
Efforts to Focus on Pre-Clinical and Clinical Research for up to 16 Early-Stage Programs Across Various Types of Cancer Multi-Year Agreements Build on Long-Term Partnership in Immuno-Oncology, Including BiTE® Therapies and now CAR T Programs THOUSAND OAKS, Calif. and HOUSTON, May 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung ...
Source: Amgen News Release - May 31, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Common chemical used in plastic packaging 'probably' causes cancer
The World Health Organization warns that styrene, which is used to make rubber and plastic packaging, raises the risk of leukaemia or nasal cancer if people are exposed to it at work. (Source: the Mail online | Health)
Source: the Mail online | Health - May 31, 2018 Category: Consumer Health News Source Type: news

MD Anderson and Amgen to accelerate early-stage treatments for several cancer types
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2018 Category: Cancer & Oncology Source Type: news

Penn-developed approach could limit toxicity of CAR T therapy in acute myeloid leukemia
(University of Pennsylvania School of Medicine) A new approach pioneered at the University of Pennsylvania's Abramson Cancer Center may provide a new path towards treating acute myeloid leukemia (AML) with CAR T cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2018 Category: Cancer & Oncology Source Type: news

CLL patient treated at Penn goes into remission thanks to single CAR T cell
(University of Pennsylvania School of Medicine) Researchers at the University of Pennsylvania's Abramson Cancer Center say a patient treated for chronic lymphocytic leukemia (CLL) in 2013 went into remission because of a single CAR T cell and the cells it produced as it multiplied, and has stayed cancer free in the five years since, with CAR T cells still present in his immune system. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2018 Category: Cancer & Oncology Source Type: news

Researchers find leukemia and lymphoma drug may benefit glioblastoma patients
(Cleveland Clinic) New Cleveland Clinic research shows for the first time that ibrutinib, an FDA-approved drug for lymphoma and leukemia, may also help treat the most common -- and deadliest -- type of brain tumor. The findings, published in Science Translational Medicine, offer hope that the drug may one day be used in patients with glioblastoma and improve poor survival rates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2018 Category: Cancer & Oncology Source Type: news

U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
TOKYO, May 29, 2018 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has accepted, with Priority R... Biopharmaceuticals, Oncology, FDA Astellas Pharma, gilteritinib, Acute Myeloid Leukemia, FLT3 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 29, 2018 Category: Pharmaceuticals Source Type: news

U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
TOKYO, May 29, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. " Astellas " ) announced today that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the company's New Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 29, 2018 Category: Drugs & Pharmacology Source Type: news

Girl, 6, bravely battles two types of rare cancer and needs bone marrow transplant
Kalea Ramos, six, from San Diego, California, was diagnosed with two forms of rare leukemia last October, leaving her in need of a bone marrow transplant - and nobody in her family is a match. (Source: the Mail online | Health)
Source: the Mail online | Health - May 28, 2018 Category: Consumer Health News Source Type: news

' Too Clean' Could Be a Trigger for Childhood Acute Leukemia'Too Clean' Could Be a Trigger for Childhood Acute Leukemia
A lack of microbial exposure among children in industrialized countries may contribute to the development of childhood B-cell acute lymphoblastic leukemia, say researchers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Weeding out childhood leukaemia – fighting cancer with nature
New research, led by cancer biologists from the University of Bristol, has shown that bone marrow cells can protect cancer cells from a plant derived anti-cancer agent called Parthenolide. (Source: University of Bristol news)
Source: University of Bristol news - May 25, 2018 Category: Universities & Medical Training Tags: ; Faculty of Biomedical Sciences; Press Release Source Type: news

Blood cancer symptoms: Pregnant women thought symptoms were just due to daily life
BLOOD cancer symptoms can include coughing or chest pain, fever and night sweats. However, they are notoriously hard to detect. This pregnant women had no idea she had leukaemia before going for a routine check-up. (Source: Daily Express - Health)
Source: Daily Express - Health - May 24, 2018 Category: Consumer Health News Source Type: news

Blood cancer symptoms: Pregnant woman thought symptoms were just due to daily life
BLOOD cancer symptoms can include coughing or chest pain, fever and night sweats. However, they are notoriously hard to detect. This pregnant woman had no idea she had leukaemia before going for a routine check-up. (Source: Daily Express - Health)
Source: Daily Express - Health - May 24, 2018 Category: Consumer Health News Source Type: news

IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Phase 3 iLLUMINATE trial met primary endpoint of progression-free survival (PFS) in patients with previously untreated CLL and Small Lymphocytic Lymphoma (SLL) compared to chlorambucil plus obinutuzumab as assessed by an Independent Review Committee (IRC) ... Biopharmaceuticals, Oncology AbbVie, IMBRUVICA, ibrutinib, GAZYVA, obinutuzumab, Chronic Lymphocytic Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 24, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: Early exposure to microbes may protect against childhood leukemia
A new analysis suggests that childhood acute lymphoblastic leukemia likely results from genetic predisposition and limited early exposure to germs. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 23, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news

New 'unified theory' of childhood leukemia raises possibility of preventing the disease
Kids who develop acute lymphoblastic leukemia may be the victims of a triple-whammy stroke of bad luck, according to a provocative new theory from a respected British cancer researcher.If the explanation turns out to be correct, it would be good news for the most common type of childhood cancer:... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - May 23, 2018 Category: Science Authors: Melissa Healy Source Type: news

Imatinib-induced Fulminant Liver Failure in CML Imatinib-induced Fulminant Liver Failure in CML
Acute liver failure can be a fatal adverse effect of chronic myeloid leukemia treatment with imatinib. Is liver transplant a viable option for these patients?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

' Best Survival Data Ever' in Young T-Cell Leukemia Patients'Best Survival Data Ever' in Young T-Cell Leukemia Patients
Moving nelarabine to the front line and combining it with methotrexate improved 4-year disease-free survival in young patients with T-cell acute lymphoblastic leukemia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

A germ-free childhood could trigger leukemia, scientist suggests
Germ-free childhoods followed by infections later in life can trigger the onset of childhood leukemia, a new study suggests. (Source: CNN.com - Health)
Source: CNN.com - Health - May 22, 2018 Category: Consumer Health News Source Type: news

Preventing Childhood Leukemia May Eventually Be Possible. As A Survivor Myself, I'm Hopeful
A prominent UK scientist has suggested that childhood leukemia may one day be preventable by priming the immune systems of babies with harmless bacteria. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 22, 2018 Category: Pharmaceuticals Authors: Victoria Forster, Contributor Source Type: news

Ultra-Clean Homes Can Raise Childhood Cancer Risk, Study Finds
LONDON (CBS Local) – A groundbreaking study into what triggers cancer has found that children who are “too hygienic” and are kept away from other kids were at greater risk for developing leukemia. The Details: A cancer study has found that children living in ultra-clean environments have higher rates of leukemia Professor Mel Greaves says children need to have their immune system “primed” by exposure to various germs Greaves found that children with siblings or who were breastfed had lower rates of the disease Professor Mel Greaves from the Institute of Cancer Research (ICR) in London h...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 22, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News childhood cancer Children Chris Melore Germs Leukemia Local TV talkers Source Type: news

Germ-free first year ‘could cause childhood leukaemia’
A GERM-FREE first year of life is one of the major causes of childhood leukaemia, a study claims. (Source: Daily Express - Health)
Source: Daily Express - Health - May 22, 2018 Category: Consumer Health News Source Type: news

Keeping babies too clean may trigger leukaemia
Researchers from The Institute of Cancer Research, London, found youngsters who are genetically at-risk of leukaemia are more likely to develop the condition if not exposed to germs. (Source: the Mail online | Health)
Source: the Mail online | Health - May 21, 2018 Category: Consumer Health News Source Type: news

Missing microbes 'cause' childhood cancer
Early exposure to microbes may help protect children against a type of leukaemia, says a UK scientist. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - May 21, 2018 Category: Consumer Health News Source Type: news